Comparison of pramipexole with and without domperidone co‐administration on alertness, autonomic, and endocrine functions in healthy volunteers

Abstract

What is already known about this subject • It is known that the dopamine receptor agonist pramipexole, used for the treatment of Parkinson's disease, often causes nausea that can be treated in patients by the co‐administration of an antiemetic, for example domperidone. • In experimental studies of pramipexole it may be necessary to administer domperidone alongside pramipexole to alleviate nausea, and as such it is necessary to know how the co‐administration of domperidone may alter the observed effects of pramipexole. What this study adds • Results from our study indicate that the co‐administration of pramipexole and domperidone may reduce the likelihood of observing an effect that is present when pramipexole is administered alone. • Although domperidone is mainly a peripherally acting drug, it appears that a high enough concentration of the drug crosses the blood–brain barrier to partially antagonize some of the autonomic actions of pramipexole. • Therefore, this report provides a cautionary note to the use of domperidone alongside pramipexole where the results of interest are those from pramipexole alone. Aims To investigate the effects of the D2‐receptor agonist pramipexole with and without the co‐administration of the peripherally acting D2‐receptor antagonist domperidone on measures of alertness, autonomic and endocrine function. Methods Sixteen male volunteers participated in four weekly sessions of pramipexole 0.5 mg, domperidone 40 mg, their combination, and placebo administered according to a balanced, double‐blind design. Alertness (visual analogue scales (VAS), critical flicker fusion frequency, pupillographic sleepiness test), autonomic (pupil diameter, light and darkness reflexes, blood pressure, heart rate, salivation, temperature) and endocrine (prolactin, thyroid‐stimulating hormone (TSH), growth hormone (GH)) functions were assessed. Data were analyzed with anova with multiple comparisons. Results The pre‐post treatment changes in VAS alertness were reduced by pramipexole with and without domperidone (mean difference from placebo (95% confidence interval), mm): pramipexole −15.75 (−23.38, −8.13), combination −11.84 (−20.77, −2.91). Treatment condition significantly affected pupil diameter measured in different ways (resting pupil diameter (F3,45 = 8.39, P < 0.001), initial diameter of the light reflex response (F3,42 = 3.78, P < 0.05), and light (F3,45 = 5.21, P < 0.005) and dark (F3,45 = 3.36, P < 0.05) diameters of the darkness reflex response). Pramipexole without domperidone consistently increased pupil diameter on all measures (P < 0.05), whereas with domperidone only the increase in resting and dark diameters reached significance. Pramipexole reduced light reflex amplitude and increased latency, whereas the combination affected latency only. Concentrations of prolactin and TSH were increased by domperidone. Pramipexole reduced prolactin and increased GH concentrations. Conclusions The attenuation of the central pupillary effects of pramipexole by domperidone indicates that domperidone h...

Mapping anhedonia onto reinforcement learning: a behavioural meta-analysis

“…Although pramipexole is a non-ergot D 2 / D 3 agonist (and is clinically used as such in Parkinson’s disease, restless leg syndrome, and occasionally in treatment-resistant MDD), it has previously been found to have behavioural effects of a DA antagonist at the low doses (0.5 mg) used in our dataset [72-74]. Similarly, low doses of the D 2 agonist cabergoline have been found to specifically reduce reward go learning [75].…”

The potential role of dopamine D3 receptor neurotransmission in cognition

“…Further, ABT-925 showed significant effect on executive function and emotion recognition in the same sample (Gross et al, 2013). Most of the evidence is derived from the effects of preferential D 3 receptor-agonists, pramipexole (5- to 7-fold D 3 /D 2 and D 4 receptor selectivity) (Brusa et al, 2003; Hubble, 2000; Rektorova et al, 2005; Samuels et al, 2006a, b, 2007) and rotigotine (20-fold D 3 /D 2 and 100-fold D 3 /D 1 receptor selectivity) (Bunten and Happe, 2006; Sanford and Scott, 2011; Scheller et al, 2009) on cognition in healthy individuals and those with PD or bipolar disorder. Thus far, the cognitive effects of preferential D 3 receptor agonists in humans are mixed (Brusa et al, 2005).…”

Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson’s Disease

“…III score was tested in order to meet the FDA's criteria for the approval of pramipexole ER in the USA [30]. [16,18,21] Lacks affinity for receptors of the dopamine D 1 subfamily a [22] Lacks affinity for a 1 -adrenergic, b-adrenergic, ACh, and serotonin 5-HT 1A and 5-HT 2 receptors [22] Demonstrated dopaminergic activity in animal models of PD [13,23] Demonstrated numerous potential neuroprotective actions in preclinical models of PD [24] ; Dopamine neuronal degeneration in pts with early PD c [25] ; Prolactin and : growth hormone levels in healthy volunteers [26] No effect on QT interval in healthy volunteers [27] Up-titration of PPX ER at faster than the recommended rate : BP and : HR in healthy volunteers d [8,10,28] Up-titration of PPX ER at the recommended rate did not : BP and : HR in pts with PD [8,10] Up-titration of PPX ER at the recommended rate occasionally caused symptomatic orthostatic hypotension in pts with PD e [10] ACh acetylcholine, BP blood pressure, HR heart rate, L-DOPA levodopa, PD Parkinson's disease, PL placebo, PPX ER pramipexole extended release, pts patients, ; decreased, : increased a D 1 subfamily includes D 1 and D 5 receptors; D 2 subfamily includes D 2 , D 3 and D 4 receptors b Binding affinity (K i ) of 3.9, 3.3, 0.5 and 3.9 nmol/L at D 2L , D 2S , D 3 and D 4 receptor subtypes, respectively [21] c p = 0.01 vs. L-DOPA; as assessed by dopamine transporter brain imaging d Albeit mean values remained within normal reference ranges e Reported in 3 % of pts with early or advanced PD who received PPX ER in two large PL-controlled trials [10] (see Sect. 4.2.2) Monotherapy with pramipexole ER administered once daily was noninferior to monotherapy with pramipexole IR administered three times daily and significantly more effective than placebo in improving activities of daily living and motor function in patients with early PD [11].…”